Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11575221 | 0.87 | KDM4E (0.48) | KDM4EHPGDALDH1A1CA1CA9 | |
| SCHEMBL11575219 | 0.87 | KDM4E (0.48) | KDM4EHPGDALDH1A1CA1CA9 | |
| D-Glutamate SCHEMBL22733592 | 0.84 | KDM4E (0.56) | KDM4EHPGDALDH1A1CYP1A2CA1 | |
| SCHEMBL30367223 | 0.83 | KDM4E (0.48) | KDM4EHPGDALDH1A1CA1CA9 | |
| SCHEMBL11179021 | 0.79 | KDM4E (0.50) | KDM4EHPGDALDH1A1CA1CA9 | |
| SCHEMBL12698767 | 0.79 | CYP1A2 (0.52) | ALDH1A1CYP1A2GRM8GRM6GRIN2D | |
| Methylamine SCHEMBL27498946 | 0.78 | BCAT2 (0.47) | KDM4EHPGDALDH1A1CYP1A2GRM8 | |
| SCHEMBL5143238 | 0.78 | KLKB1 (0.41) | KDM4EHPGDALDH1A1CYP1A2CA1 | |
| Methane SCHEMBL27519431 | 0.78 | NR4A1 (0.49) | KDM4EHPGDALDH1A1CYP1A2GRM8 | |
| SCHEMBL8231314 | 0.78 | FPR1 (0.44) | KDM4EHPGDALDH1A1CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161400-A1 | ANTIDIABETIC ORAL INSULIN BIGUANIDE COMBINATION | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2018-06-14 | — | — | US | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-8324156-B2 | Oral insulin therapies and protocol | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-12-04 | — | — | US | claimed |
| JP-4659358-B2 | — | — | 2011-03-30 | — | — | JP | claimed |
| EP-2248531-A1 | Antidiabetic oral insulin-biguanide combination | Emisphere Technologies, Inc. (US) | 2010-11-10 | — | — | EP | claimed |
| US-20100048454-A1 | Antidiabetic oral insulin-biguanide combination | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-02-25 | — | — | US | claimed |
| US-20090318331-A1 | ORAL INSULIN THERAPIES AND PROTOCOL | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-12-24 | — | — | US | claimed |
| US-20090253614-A1 | ORAL INSULIN THERAPIES & PROTOCOL | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-10-08 | — | — | US | claimed |
| EP-1773376-A2 | ANTIDIABETIC ORAL INSULIN-BIGUANIDE COMBINATION | Emisphere Technologies, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060234913-A1 | Oral insulin therapy | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2006-10-19 | — | — | US | claimed |
| WO-2006017541-A2 | ANTIDIABETIC ORAL INSULIN-BIGUANIDE COMBINATION | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| EP-1605895-A2 | ORAL INSULIN THERAPIES AND PROTOCOL | Emisphere Technologies, Inc. (US) | 2005-12-21 | — | — | EP | claimed |
| US-20050203001-A1 | Treating impaired glucose tolerance and early and late stage diabetes; improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-09-15 | — | — | US | claimed |
| JP-2005525308-A | — | — | 2005-08-25 | — | — | JP | claimed |
| EP-1469812-A2 | ORAL INSULIN THERAPY | Emisphere Technologies, Inc. (US) | 2004-10-27 | — | — | EP | claimed |
| WO-2004080401-A2 | ORAL INSULIN THERAPIES AND PROTOCOL | EMISPHERE TECHNOLOGIES, INC. (US) | 2004-09-23 | — | — | WO | claimed |
| US-20030198666-A1 | Oral insulin therapy | EMISPHERE TECHNOLOGIES, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003057170-A2 | ORAL INSULIN THERAPY | EMISPHERE TECHNOLOGIES, INC. (US) | 2003-07-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253614-A1 | ORAL INSULIN THERAPIES & PROTOCOL | IAPP, GPR119, GCG | KDM4E 4566/4885HPGD 3220/4885ALDH1A1 4482/4885 |
| US-20050203001-A1 | Treating impaired glucose tolerance and early and late stage diabetes; improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring | IAPP, GPR119, GCG | KDM4E 4282/4885HPGD 3069/4885ALDH1A1 4019/4885 |
| US-20180161400-A1 | ANTIDIABETIC ORAL INSULIN BIGUANIDE COMBINATION | IAPP, SLC2A3, SLC2A4 | KDM4E 3809/4885HPGD 2465/4885ALDH1A1 2967/4885 |
| US-20090318331-A1 | ORAL INSULIN THERAPIES AND PROTOCOL | IAPP, GPR119, GCG | KDM4E 4484/4885HPGD 3169/4885ALDH1A1 4564/4885 |
| US-20030198666-A1 | Oral insulin therapy | INSR, IAPP, SLC2A4 | KDM4E 4852/4885HPGD 1676/4885ALDH1A1 4023/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | KDM4E 4162/4885HPGD 1489/4885ALDH1A1 3725/4885 |
| US-20060234913-A1 | Oral insulin therapy | IAPP, INSR, SI | KDM4E 4848/4885HPGD 1315/4885ALDH1A1 3937/4885 |
| US-20100048454-A1 | Antidiabetic oral insulin-biguanide combination | IAPP, SLC2A3, SLC2A4 | KDM4E 4392/4885HPGD 2482/4885ALDH1A1 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.